Vivo Capital, LLC Avadel Pharmaceuticals PLC Transaction History

Vivo Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$12.55 - $17.22 $1.56 Million - $2.14 Million	-124,329 Reduced 3.04%	3,972,099 $67.1 Million
Q3 2023 Nov 08, 2023	BUY	$10.3 - $15.99 $2.75 Million - $4.27 Million	266,851 Added 6.97%	4,096,428 $42.2 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $577,818 - $1.12 Million	68,139 Added 1.81%	3,829,577 $63.1 Million
Q1 2023 May 12, 2023	BUY	$6.41 - $9.95 $6.46 Million - $10 Million	1,007,343 Added 36.58%	3,761,438 $34.5 Million
Q4 2022 Feb 13, 2023	SELL	$5.02 - $10.0 $918,649 - $1.83 Million	-182,998 Reduced 6.23%	2,754,095 $19.7 Million
Q1 2021 May 17, 2021	SELL	$6.61 - $10.07 $3.89 Million - $5.93 Million	-589,000 Reduced 16.7%	2,937,093 $26.6 Million
Q2 2020 Aug 14, 2020	SELL	$7.25 - $11.75 $357,649 - $579,639	-49,331 Reduced 1.38%	3,526,093 $28.5 Million
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $14.5 Million - $38 Million	3,575,424 New	3,575,424 $28.4 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.